Skip to main content
Fig. 2 | Biomarker Research

Fig. 2

From: Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma

Fig. 2

Best response by median NER and NLR. A) < mNER: CR = 5%, PR = 35%, SD = 29%, NE = 2%. >mNER: CR = 2%, PR = 20%, SD = 18%, PD = 55%, NE = 5%. Odds ratio for ORR = 2.39 (95% CI 1.03–5.52), p = 0.04. B) < mNLR: CR = 4%, PR = 27%, SD = 27%, PD = 42%, NE = 0%. >mNLR: CR = 4%, PR = 27%, SD = 20%, PD = 42%, NE = 7%. CR = complete response, PR = partial response, SD = stable disease, NE = not evaluable. Odds ratio for ORR = 1.00 (0.44–2.25), p = 1.00)

Back to article page